{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:47:02Z","timestamp":1782992822793,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment-resistant major depressive disorder with high-risk suicidal ideation is a psychiatric emergency that requires rapid and effective intervention. Although intranasal esketamine and intermittent theta-burst stimulation (iTBS) are time-efficient therapeutic options, clinical reports describing their combined use in an accelerated inpatient schedule are limited, particularly in acutely high-risk patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 29-year-old woman with recurrent major depressive disorder was hospitalized for severe depressive symptoms and high-risk suicidal ideation after inadequate responses to several antidepressant trials, augmentation therapy, psychotherapy, and a standard course of repetitive transcranial magnetic stimulation. Her baseline symptom severity scores were as follows: Patient Health Questionnaire-9 (PHQ-9), 15; Hamilton Depression Rating Scale (HAMD), 27; and Beck Depression Inventory (BDI), 41. After providing written informed consent, she received intranasal esketamine (84 mg) and an accelerated iTBS protocol targeting the left dorsolateral prefrontal cortex (Beam F3 localization), with 10 iTBS sessions delivered over 4 treatment days (total 6,000 pulses).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patient\u2019s depressive symptoms improved during the acute treatment course (PHQ-9: 15\u219211; HAMD: 27\u219220; BDI: 41\u219228), and she reported an improvement in suicidal ideation. Her clinical status remained stable at the 2-week follow-up (PHQ-9\u00a0=\u00a08; HAMD\u00a0=\u00a017; and BDI\u00a0=\u00a023). An exploratory device-derived stress index obtained using the Stress Electroencephalogram Assessment (SEA) system decreased from 7 to 3, consistent with clinical improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that the combination of intranasal esketamine and accelerated iTBS is feasible in inpatient settings for treating severe depression with high-risk suicidal ideation. Additional controlled studies are required to evaluate the efficacy, optimal sequencing, safety monitoring, and durability of this combined approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1837402","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:27:02Z","timestamp":1782991622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Intranasal esketamine and accelerated intermittent theta-burst stimulation for severe treatment-resistant depression with suicidal ideation"],"prefix":"10.3389","volume":"17","author":[{"given":"Chun-Hung","family":"Chang","sequence":"first","affiliation":[{"name":"An Nan Hospital, China Medical University","place":["Tainan, Taiwan"]},{"name":"College of Medicine, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Der","family":"Hsia","sequence":"additional","affiliation":[{"name":"An Nan Hospital, China Medical University","place":["Tainan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nursing, National Tainan Junior College of Nursing","place":["Tainan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ho","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chi Mei Medical Center","place":["Tainan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjung","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Aging Medicine, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Chi","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tzu-Chi General Hospital","place":["Hualien, Taiwan"]},{"name":"Institute of Medical Sciences, Tzu Chi University","place":["Hualien, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41572-023-00454-1","article-title":"Major depressive disorder","volume":"9","author":"Marx","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.2833","article-title":"Determinants and outcomes of suicidal behavior among patients with major depressive disorder","volume":"80","author":"Lundberg","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A Star*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: Focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discov Today"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.1317","article-title":"Esketamine monotherapy in adults with treatment-resistant depression: A randomized clinical trial","volume":"82","author":"Janik","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - First FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02630-5","article-title":"Theta burst stimulation for depression: A systematic review and network and pairwise meta-analysis","volume":"29","author":"Kishi","year":"2024","journal-title":"Mol Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2023.12.004","article-title":"Accelerated theta burst stimulation: Safety, efficacy, and future advancements","volume":"95","author":"Cole","year":"2024","journal-title":"Biol Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.brs.2023.07.015","article-title":"Coadministration of rTMS and nasal ketamine on patients with MDD \u2013 a retrospective study","volume":"16","author":"Caussat","year":"2023","journal-title":"Brain Stimul"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.psycr.2025.100250","article-title":"Efficacy of combined theta burst stimulation (TBS) and intranasal esketamine in an ECT-resistant depressive patient: A case report","volume":"4","author":"Mole\u00f3n-Ruiz","year":"2025","journal-title":"Psychiatry Res Case Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"B13","article-title":"Rating depressive patients","volume":"41","author":"Hamilton","year":"1980","journal-title":"J Clin Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1\u201325","DOI":"10.3390\/bios11120499","article-title":"Resting-state EEG signal for major depressive disorder detection: A systematic validation on a large and diverse dataset","volume":"11","author":"Wu","year":"2021","journal-title":"Biosens-Basel"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3109\/09540261.2013.816269","article-title":"EEG biomarkers in major depressive disorder: Discriminative power and prediction of treatment response","volume":"25","author":"Olbrich","year":"2013","journal-title":"Int Rev Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2018.00521","article-title":"EEG frequency bands in psychiatric disorders: A review of resting state studies","volume":"12","author":"Newson","year":"2018","journal-title":"Front Hum Neurosci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2008.09.006","article-title":"An efficient and accurate new method for locating the F3 position for prefrontal TMS applications","volume":"2","author":"Beam","year":"2009","journal-title":"Brain Stimulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clinph.2019.11.002","article-title":"Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)","volume":"131","author":"Lefaucheur","year":"2020","journal-title":"Clin Neurophysiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1267647","article-title":"Transcranial magnetic stimulation and ketamine: Implications for combined treatment in depression","volume":"17","author":"Debowska","year":"2023","journal-title":"Front Neurosci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19070720","article-title":"Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression","volume":"177","author":"Cole","year":"2020","journal-title":"Am J Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx379","article-title":"High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression","volume":"141","author":"Williams","year":"2018","journal-title":"Brain: A J Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.3646","article-title":"The new antibiotic mantra-\"Shorter is better","volume":"176","author":"Spellberg","year":"2016","journal-title":"JAMA Intern Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02187","article-title":"Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use","volume":"5","author":"Best","year":"2019","journal-title":"Heliyon"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06573-1","article-title":"Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: A pilot study","volume":"241","author":"Shanok","year":"2024","journal-title":"Psychopharmacology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.brs.2014.02.010","article-title":"Modulation of inhibitory activity markers by intermittent theta-burst stimulation in rat cortex is NMDA-receptor dependent","volume":"7","author":"Labedi","year":"2014","journal-title":"Brain Stimul"},{"key":"B28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/etm.2023.11810","article-title":"Esketamine for treatment-resistant depression: A review of clinical evidence (review)","volume":"25","author":"Vasiliu","year":"2023","journal-title":"Exp Ther Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0013","article-title":"Accelerated theta-burst stimulation for treatment-resistant depression: A randomized clinical trial","volume":"82","author":"Ramos","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2007.01.021","article-title":"The after-effect of human theta burst stimulation is NMDA receptor dependent","volume":"118","author":"Huang","year":"2007","journal-title":"Clin Neurophysiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40263-020-00699-4","article-title":"Cardiac safety of esketamine nasal spray in treatment-resistant depression: Results from the clinical development program","volume":"34","author":"Doherty","year":"2020","journal-title":"CNS Drugs"},{"key":"B32","unstructured":"SPRAVATO\u00ae (Esketamine) Nasal Spray Prescribing Information\n          \n          \n          \n          2023"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1837402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:27:13Z","timestamp":1782991633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1837402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":32,"alternative-id":["10.3389\/fpsyt.2026.1837402"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1837402","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1837402"}}